CTOs on the Move

MEDISCA

www.medisca.com

 
With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.medisca.com
  • 6090 Henri-Bourassa Blvd W
    Saint-Laurent, QC CAN H4R 3A6
  • Phone: 514.333.7811

Executives

Name Title Contact Details

Similar Companies

Arete Pharmacy Network

American Associated Pharmacies and H. D. Smith combined respective pharmacy services administrative organizations (PSAO) into a new PSAO, servicing more than 2,300 independent retail pharmacies across the United States. Arete Pharmacy Network will combine and succeed H. D. Smith`s Third Party Network and AAP`s United Drugs. Arete Pharmacy Network focuses on independents and community pharmacies, with a focus on managed care contracting and expanded tools and services, allows pharmacies to deliver quality care as a differentiator in their communities. Arete Pharmacy Network can help effectively manage the financial, quality and operational aspects of your pharmacy business.

OrthoTennessee

OrthoTennessee provides the finest orthopedic clinics in East Tennessee, improving lives through patient-centered care, orthotics, therapy and imaging.

Apotex Fermentation

Apotex Fermentation, Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triangle Compounding Pharmacy

Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chugai Pharma

Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.